Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - etoricoxib, quantity: 30 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cipla etoricoxib is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - etoricoxib, quantity: 120 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cipla etoricoxib is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - codeine phosphate hemihydrate, quantity: 12.8 mg; ibuprofen, quantity: 200 mg - tablet, film coated - excipient ingredients: glyceryl behenate; magnesium stearate; maize starch; lactose monohydrate; purified water; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 6000 - cipla pain relief ibuprofen plus is used for temporary relief of acute moderate pain and inflammation

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - etoricoxib, quantity: 90 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cipla etoricoxib is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - etoricoxib, quantity: 90 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cipla etoricoxib is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - etoricoxib, quantity: 60 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin - cipla etoricoxib is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - etoricoxib, quantity: 30 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cipla etoricoxib is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - etoricoxib, quantity: 120 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cipla etoricoxib is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - isoprenaline hydrochloride, quantity: 1 mg - injection, solution - excipient ingredients: disodium edetate; sodium chloride; sodium citrate dihydrate; citric acid; hydrochloric acid; sodium hydroxide; water for injections - cipla isoprenaline is indicated: - for mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. - for serious episodes of heart block and adams-stokes attacks (except when caused by ventricular tachycardia or fibrillation) (see section 4.3 contraindications). - for use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, are available (see section 4.3 contraindications). - for brochospasm occurring during anaesthesia. - as an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolaemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure and cariodgenic shock (see section 4.4 special warnings and precautions for use).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - isoprenaline hydrochloride, quantity: 200 microgram - injection, solution - excipient ingredients: disodium edetate; sodium chloride; sodium citrate dihydrate; citric acid; hydrochloric acid; sodium hydroxide; water for injections - cipla isoprenaline is indicated: - for mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. - for serious episodes of heart block and adams-stokes attacks (except when caused by ventricular tachycardia or fibrillation) (see section 4.3 contraindications). - for use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, are available (see section 4.3 contraindications). - for brochospasm occurring during anaesthesia. - as an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolaemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure and cariodgenic shock (see section 4.4 special warnings and precautions for use).